About Eikon
Eikon is a company based in Hayward (United States) founded in 2019 by Robert Tjian, Luke Lavis, and Eric Betzig. Eikon has raised $1.16 billion across 4 funding rounds from investors including ARE, T. Rowe Price and StepStone Group. Eikon offers products and services including Therapeutic Platform, Pipeline, and Eikon Systems. Eikon operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, Nimbus Therapeutics and BioNTech, among others.
- Headquarter Hayward, United States
- Founders Robert Tjian, Luke Lavis, Eric Betzig
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Eikon Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.16 B (USD)
in 4 rounds
-
Latest Funding Round
$350.7 M (USD), Series D
Feb 14, 2025
-
Investors
ARE
& 21 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Eikon
Eikon is a publicly listed company on the NASDAQ with ticker symbol EIKN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Eikon
Eikon offers a comprehensive portfolio of products and services, including Therapeutic Platform, Pipeline, and Eikon Systems.
Platform for developing and managing therapeutic products
System for advancing therapeutic drug pipelines
Systems for reporting and handling product safety concerns
People of Eikon
Unlock access to complete
Unlock access to complete
Software Development Team
41 people
Leadership Team
31 people
Senior Team
14 people
Human Resources and Administration
7 people
Board Team
6 people
Finance and Accounting
6 people
Data Analysis and Operations Team
5 people
Staff Team
5 people
Unlock access to complete
Funding Insights of Eikon
Eikon has successfully raised a total of $1.16B across 4 strategic funding rounds. The most recent funding activity was a Series D round of $350.7 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Eikon
Eikon has secured backing from 22 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, T. Rowe Price and StepStone Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early-stage technology companies are funded by Lux Capital.
|
Locked | Locked | Locked | |
|
AME Cloud Ventures is focused on investing in data-driven technology companies.
|
Locked | Locked | Locked | |
|
Early-stage investments in US life science startups are focused on.
|
Locked | Locked | Locked |
Investor details for Eikon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eikon
Investment portfolio details for Eikon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Eikon
Detailed financials for Eikon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eikon Comparisons
Peer comparison for Eikon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Eikon
Eikon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, Nimbus Therapeutics and BioNTech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of Eikon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eikon
Complete news archive for Eikon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eikon
Eikon was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Eikon is headquartered in Hayward, United States. It is registered at Hayward, California, United States.
Roger M Perlmutter is the current CEO of Eikon.
Eikon is a funded company, having raised a total of $1.16B across 4 funding rounds to date.
Eikon was founded in 2019 and is headquartered in Hayward, United States. The company operates in the biotechnology sector, focusing on drug discovery through a therapeutic platform. Protein dynamics are analyzed by researchers using live-cell super-resolution microscopy integrated with computing and engineering technologies. This approach supports the identification and evaluation of potential drug targets.
Eikon's top competitors include ADMA Biologics, Nimbus Therapeutics and BioNTech.
Eikon offers Therapeutic Platform, Pipeline, and Eikon Systems.
Yes, Eikon is publicly traded on NASDAQ under the ticker symbol EIKN.
Eikon has 22 investors. Key investors include ARE, T. Rowe Price, StepStone Group, Schroders, and CPP Investments.
The ticker symbol of Eikon is EIKN on NASDAQ.